Pinch-zoom for details.
The offering
Final price
$14.00
per share, from the final prospectus
Shares offered
8.33M
+1.25M over-allotment option
Raise at the final price
$117M
8,333,334 × $14, before fees
What the company does
Clinical-stage biotech developing medicines based on tissue regulatory T cells (Tregs) to restore immune balance in autoimmune and inflammatory diseases.
Things to weigh
- The filing's financial tables couldn't be read reliably, so none are shown here.
Risks
- We are a clinical-stage biopharmaceutical company with a limited operating history…
- Raising additional capital may cause dilution to our stockholders, including purchasers of common stock in this offering…
- Clinical development is lengthy and expensive, characterized by uncertain outcomes, with results of earlier studies…
- Delays or difficulties in the enrollment and dosing of patients in clinical trials delay or prevent receipt of necessary regulatory approvals
- Any significant adverse events or undesirable side effects caused by our product candidates may delay or prevent regulatory approval…
- We face potential competition from different sources that have made substantial investments into the rapid development of novel treatments for…
The filing's own risk-factor headings, shortened.
Strategy
The filing doesn't set out its strategy in a list we could read.
Source: TRex Bio, Inc.'s Form 424B4, filed with the SEC on Oct 9, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.